Sparreboom A - Search Results

1

Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.

Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD. Zimmerman EI, et al. Among authors: sparreboom a. Cancer Res. 2016 Jan 1;76(1):117-26. doi: 10.1158/0008-5472.CAN-15-0694. Epub 2015 Dec 17. Cancer Res. 2016. PMID: 26677977 Free PMC article.

2

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Sparreboom A, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):183-90. doi: 10.1016/s1570-0232(02)00167-8. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 12031845

3

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A. Baker SD, et al. Among authors: sparreboom a. J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8. doi: 10.1093/jnci/94.24.1883. J Natl Cancer Inst. 2002. PMID: 12488482

4

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD. Sparreboom A, et al. Clin Cancer Res. 2003 Jan;9(1):151-9. Clin Cancer Res. 2003. PMID: 12538463

5

Distribution of paclitaxel in plasma and cerebrospinal fluid.

Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: sparreboom a. Anticancer Drugs. 2003 Jun;14(5):365-8. doi: 10.1097/00001813-200306000-00007. Anticancer Drugs. 2003. PMID: 12782943 Clinical Trial.

6

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Mathijssen RH, et al. Among authors: sparreboom a. Clin Cancer Res. 2003 Aug 15;9(9):3246-53. Clin Cancer Res. 2003. PMID: 12960109

7

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Among authors: sparreboom a. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

8

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.

Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A. Baker SD, et al. Among authors: sparreboom a. Anal Biochem. 2004 Jan 15;324(2):276-84. doi: 10.1016/j.ab.2003.09.038. Anal Biochem. 2004. PMID: 14690692

9

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Baker SD, et al. Among authors: sparreboom a. Clin Cancer Res. 2004 Mar 15;10(6):1976-83. doi: 10.1158/1078-0432.ccr-0842-03. Clin Cancer Res. 2004. PMID: 15041715 Clinical Trial.

10

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Rudek MA, et al. Among authors: sparreboom a. Eur J Cancer. 2004 May;40(8):1170-8. doi: 10.1016/j.ejca.2003.12.026. Eur J Cancer. 2004. PMID: 15110880

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters